DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages.

Home arrow-right-small-blue Fungal skin infections arrow-right-small-blue Oral antifungal agents CME. Oral antifungal drugs currently in use include itraconazole, fluconazole, ketoconazole and terbinafine. They are reserved for extensive or severe infection for which topical antifungal agents are inappropriate or ineffective, because of high cost, potential side effects and drug interactions.

Griseofulvin is not discussed as it is no longer available in New Zealand. Nor is nystatin, as it is only appropriate for intestinal candidiasis. Voriconazole has recently become available but is reserve for the treatment of serious and refractory fungal infections in hospitalised patients.

It should be taken after a fatty meal, preferably with an acidic drink such as orange juice. Dosing regimes depend on the skin condition, its duration and severity, and need for prophylaxis. For example:. Nausea is the most common side effect. It has been reported to cause congestive cardiac failure and serious rashes.

The main concern with azoles is serious interactions with other medications. As itraconazole needs acid for its absorption, antacids, H2 antagonists and omeprazole should not be taken for 2 hours after itraconazole.

Itraconazole is not thought to interact with the oral contraceptive pill and must be avoided in pregnancy. It is not registered for nail infections. The dose and duration depends on the nature and severity of infection.

The main contraindication is concomitant administration with cisapride. Stop using the medicine if you have these severe side effects, and see a GP or pharmacist to find an alternative.

If you think a medicine has made you unwell, you can report this side effect through the Yellow Card Scheme. Some antifungal medicines can be used to treat children and babies — for example, miconazole oral gel can be used for oral thrush in babies.

But different doses are usually needed for children of different ages. Speak to a pharmacist or GP for more advice. Page last reviewed: 03 April Next review due: 03 April Home Health A to Z Back to Health A to Z. Antifungal medicines. Infections antifungals can treat Fungal infections commonly treated with antifungals include: ringworm athlete's foot fungal nail infection vaginal thrush some types of severe dandruff Some fungal infections can grow inside the body and need to be treated in hospital.

Examples include: aspergillosis , which affects the lungs fungal meningitis , which affects the brain You're more at risk of getting one of these more serious fungal infections if you have a weakened immune system — for example, if you're taking medicines to suppress your immune system.

Types of antifungal medicines You can get antifungal medicines as: a cream, gel, ointment or spray a capsule, tablet or liquid an injection a pessary: a small and soft tablet you put inside the vagina Common names for antifungal medicines include: clotrimazole Canesten econazole miconazole terbinafine Lamisil fluconazole Diflucan ketoconazole Daktarin nystatin Nystan amphotericin How antifungal medicines work Antifungal medicines work by either: killing the fungus preventing the fungus from growing When to see a pharmacist or GP See a pharmacist or GP if you think you have a fungal infection.

Things to consider when using antifungal medicines Before taking antifungal medicines, speak to a pharmacist or GP about: any existing conditions or allergies that may affect your treatment for fungal infection the possible side effects of antifungal medicines whether the antifungal medicine may interact with other medicines you may already be taking whether your antifungal medicine is suitable to take during pregnancy or while breastfeeding — many are not suitable You can also check the patient information leaflet that comes with your antifungal medicine for more information.

Side effects of antifungal medicines Antifungal medicines may cause side effects. They can include: itching or burning redness feeling sick tummy abdominal pain diarrhoea a rash Occasionally, antifungal medicines may cause a more severe reaction, such as: an allergic reaction — your face, neck or tongue may swell and you may have difficulty breathing a severe skin reaction — such as peeling or blistering skin liver damage very rarely — you may have loss of appetite, vomiting, nausea, jaundice , dark pee or pale poo, tiredness or weakness Stop using the medicine if you have these severe side effects, and see a GP or pharmacist to find an alternative.

Itraconazole and posaconazole are excluded here, due to lack of intravenous formulations and scant evidentiary support in critical illness. More common drug-drug interactions are discussed below.

However, it's always optimal to check for interactions using 🧮 MedScape's drug interaction checker. Echinocandins overall have a relatively favorable safety profile generally superior to either amphotericin or azoles. Liposomal amphotericin has largely replaced older deoxycholate formulations, as liposomal amphotericin is less toxic but equally effective.

Want to Download the Episode? Right Click Here and Choose Save-As. We are the EMCrit Project , a team of independent medical bloggers and podcasters joined together by our common love of cutting-edge care, iconoclastic ramblings, and FOAM.

Home EMCrit PulmCrit IBCC ODR About About EMCrit PulmCrit — The Full Story EMCrit FAQ Subscribe to the Newsletter Contact Join Why Should I Become a Member? Questions Before Joining FAQ Join Now! ToC About the IBCC Tweet Us RSS IBCC Podcast.

overview back to contents. azoles back to contents. echinocandins micaFUNGIN, caspoFUNGIN, anidulaFUNGIN back to contents.

liposomal amphotericin back to contents. podcast back to contents. mp3 Want to Download the Episode?

References Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med.

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Voriconazole use for endemic fungal infections.

Antimicrob Agents Chemother. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis. Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit DALI patients Study.

Crit Care. doi: Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi SECURE : a phase 3, randomised-controlled, non-inferiority trial. Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses. Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.

A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole. Eur J Drug Metab Pharmacokinet. Tolerability profile of the current antifungal armoury.

J Antimicrob Chemother. Isavuconazole: A new broad-spectrum azole. Clinical responses in patients with invasive aspergillosis appear slightly better in the lipid formulation-treated groups compared with retrospective case control groups treated with conventional amphotericin B. Some important questions about the use of amphotericin B lipid preparations remain unanswered.

Do they have long-term toxicity? Is there an optimal dose schedule and what is the most cost-effective way to use them? Unfortunately, although amphotericin B lipid preparations have reduced nephrotoxicity they have not produced substantial improvements in efficacy in many of the clinical settings in which they have been evaluated.

Some physicians have used a locally prepared variant of lipid-associated amphotericin B made by mixing conventional amphotericin B with Intralipid, Kabi Pharmacia, Saint-Quentin-en-Yvelines, France, for intravenous infusion.

Licensed preparations of lipid formulations of amphotericin B should be considered in patients with invasive fungal infections who have dose-limiting renal insufficiency, in patients intolerant of amphotericin B and for specific fungal infections that are progressive despite treatment with amphotericin B.

A liposomal preparation of nystatin has been studied in neutropenic animals with invasive pulmonary aspergillosis rabbits and disseminated aspergillosis mice. Liposomal nystatin improved survival and reduced the tissue burden of aspergillus in these neutropenic animals.

A new polyene, SPA-S, has been studied in vitro against strains of Candida, Cryptococcus and Saccharomyces spp. and has better activity in vitro than conventional amphotericin B.

The antifungal activity of 5-fluorocytosine was discovered later and was reported in in a murine model of candidosis. Uridine 5-monophosphate pyrophosphorylase then converts 5-fluorouracil into fluorodeoxyuridine monophosphate, which inhibits thymidylate synthetase and interferes with DNA synthesis.

Although flucytosine is active in vitro against Candida spp. including C. glabrata , C. neoformans and Aspergillus spp. Although flucytosine, primarily in combination with amphotericin B, is used by some clinicians in the treatment of candida endophthalmitis and meningitis, cryptococcal meningitis and in trichosporonosis, 1 ,12 ,13 the development of newer, more effective and less toxic antifungal agents is likely to decrease flucytosine use in the future.

The initial azole compounds were the imidazoles clotrimazole, miconazole and ketoconazole , which were then followed by the triazoles, fluconazole and itraconazole. The azoles inhibit fungal cytochrome P 3A-dependent Cα-demethylase which is responsible for the conversion of lanosterol to ergosterol.

This leads to the depletion of ergosterol in the fungal cell membrane. The azoles are primarily active against C. albicans, C. neoformans, C. immitis, H. capsulatum, B. dermatitidis, P. brasiliensis; C. glabrata, Aspergillus spp.

and zygomycetes are resistant to currently available azoles. Clotrimazole, discovered in , 42 cannot be given parenterally, has poor oral absorption and is used for the treatment of oral and vaginal candidosis. An intravenous preparation was marketed but this had suboptimal efficacy and it is now rarely used.

Ketoconazole was discovered in , and has good oral absorption, a broad spectrum of activity and low toxicity, although it may be hepatotoxic and does produce endocrine abnormalities by suppression of testosterone and ACTH-stimulated cortisol synthesis. Oral ketoconazole is effective in patients with candidosis, coccidioidomycosis, blastomycosis, histoplasmosis, paracoccidioidomycosis and cutaneous dermatophyte infections.

Ketoconazole is highly protein bound, has poor CNS penetration and is not suitable for treating CNS infections. Fluconazole was formulated in It is a novel bi-striazole, is metabolically stable and water soluble and has low lipophilicity and plasma protein binding.

It is active by both oral and intravenous routes which have identical pharmacokinetics, i. once-daily dosing, high blood levels and rapid equilibration of drug in the body with good tissue distribution, including penetration into the cerebrospinal fluid. Fluconazole is well tolerated and has a very low incidence of side effects and a broad spectrum of antifungal activity, except against Aspergillus spp.

Fluconazole is one of the most effective agents for the treatment of oropharyngeal and oesophageal candidosis, especially in patients with AIDS or cancer, and is extremely effective for the treatment of vaginal candidosis. Fluconazole has emerged as the drug of choice for coccidioidal meningitis, 1 ,2 ,50 although it is no more effective than other azoles for disseminated non-meningeal coccidioidomycosis.

Itraconazole, discovered in , is another triazole antifungal agent with broad-spectrum antifungal activity, including activity against Aspergillus spp. It is very insoluble, is only available in oral form and may be given once daily.

However, higher does not to exceed a total daily dose of mg may be required in serious infections and should be given in two divided doses each day.

Since its bioavailability after oral administration may be erratic, maximal absorption is optimal when itraconazole is given with meals. Itraconazole has established efficacy as primary treatment and maintenance of mild-to-moderate, non-meningeal histoplasmosis in HIV-infected patients and for prevention of relapse in AIDS patients with disseminated histoplasmosis.

Prolonged oral absorption, with slow attainment of steady-state drug levels, and the lack of an intravenous formulation are impediments to itraconazole treatment. It has a chemical structure similar to fluconazole and has broad antifungal activity including in-vitro and in-vivo activity against Aspergillus spp.

Phase III clinical trials are nearly completed. SCH is a potent antifungal triazole with excellent in-vitro activity against Candida spp. and zygomycetes and potent efficacy in animal models of pulmonary blastomycocis, cerebral cryptococcosis, disseminated histoplasmosis, systemic coccidioidomycosis and systemic candidosis.

BMS ER is a very potent antifungal triazole with excellent in-vitro and in-vivo activity against Candida spp. neoformans, Aspergillus fumigatus, Trichosporon beigelli and P. The echinocandins are cyclic lipopeptide fungicidal agents. They act by preventing cell wall synthesis by non-competitive inhibition of 1,3-β- d -glucan synthase, an enzyme which is absent in mammalian cells.

The echinocandin compound, LY , is nearest to clinical development. It has excellent activity against Candida and Aspergillus spp. in vitro and in animal models. In clinical studies, LY is well tolerated and has linear kinetics and a long plasma half-life 30—40 h so that once-daily dosing is anticipated.

The pneumocandins are echinocandin analogues one of the classes of echinocandin lipopeptides. They are cyclic hexapeptides which inhibit 1,3-β- d -glucan synthase which synthesizes a critical structural cell wall component. They also have activity against Candida and Aspergillus spp. A few pneumocandin compounds have been developed but only MK L has undergone substantial investigation.

The pradimicins and benanomicins are fungicidal compounds. They appear to bind, in a calcium-dependent manner, to cell wall mannoproteins and this causes osmotic lysis and leakage of intracellular contents, particularly potassium, ultimately leading to cell death. Calcium-dependent binding to mammalian cells has not been observed with this class of antifungal agents.

BMS was shown to be effective, though less active than conventional amphotericin B, in animal models of aspergillosis, candidosis and cryptococcosis, 1 ,2 ,7 ,76 ,77 but clinical investigation with BMS has been discontinued because of hepatotoxicity in human volunteers.

The nikkomycins are competitive inhibitors of fungal chitin synthase enzymes which are necessary for fungal cell wall synthesis.

Chitin is a linear polymer of β- 1,4 -linked N -acetylglucosamine residues and is synthesized on the cytoplasmic surface of the plasma membrane. Nikkomycin Z SP is effective in vitro and in vivo against the chitinous, dimorphic fungi C.

immitis and B. dermatitidis, but only modestly active in vitro against C. neoformans and H. neoformans and A. fumigatus, and in vivo against H. Very recently, a new synthetic antifungal agent, l -lysyl- l -norvalyl- N 3 - 4-methoxylfumaroyl - l -2,3-diaminopropanoic acid Lys-Nva-FMDP , which acts as an inhibitor of glucosephosphate synthase an enzyme which catalyses the first step in chitin biosynthesis , has been shown to inhibit growth of H.

capsulatum in vitro and in vivo. Recombinant human chitinase was recently produced. It was found to have efficacy in animal models of candidosis and aspergillosis, but was found to have significantly better activity when combined with conventional amphotericin B.

The allylamines and thiocarbamates are synthetic fungicidal agents that are reversible, non-competitive inhibitors of squalene epoxidase, an enzyme which, together with squalene cyclase, converts squalene to lanosterol.

In fungal cells, if squalene is not converted to lanosterol, the conversion of lanosterol to ergosterol is prevented. The resulting ergosterol depletion affects fungal cell membrane structure and function.

Naftifine is a topical preparation whereas terbinafine Lamisil; SF, Sandoz Pharmaceuticals is an oral systemic agent. The allylamine, naftifine, is considered an effective topical agent for treatment of dermatophyte infections of the skin.

Terbinafine has good in-vitro activity against Aspergillus spp. and other filamentous fungi, but variable activity against yeasts. However, terbinafine has been shown to be effective in vitro against some strains of Aspergillus spp.

boydii, when combined with azoles or amphotericin B, 1 ,83 ,84 ,85 ,86 and in an animal model of aspergillosis when combined with amphotericin B. The sordarins are a new class of potential antifungal agents. They inhibit protein synthesis in pathogenic fungi: the primary target for sordarin activity has been identified recently as elongation factor 2.

A number of new sordarins are being evaluated, including GM, GM, GM, GM, GM and GR neoformans, P. carinii and some filamentous fungi. or Scedosporium apiospermum. Cationic peptides, both naturally occurring and synthetic derivatives, bind to ergosterol and cholesterol in fungal cell membranes, ultimately leading to cell lysis.

neoformans and Fusarium spp. Naturally occurring cationic peptides include cecropins, dermaseptins, indolicin, histatins, bactericidal permeability-increasing factor BPI , lactoferrin and defensins. The search for new antifungal agents has been expanded as progress in molecular biology has led to a better understanding of important and essential pathways in fungal cell growth and multiplication.

A number of new compounds, some with unidentified mechanisms of action, are under study. Some are quite active in vitro against Candida spp. including azole-resistant strains , C. neoformans, A. fumigatus and Fusarium spp. albicans in thermally injured mice. The discovery of new molecular targets in both yeasts and filamentous fungi that will render these organisms susceptible to novel antifungal drugs is likely to continue in view of the major challenge by systemic fungal infections in clinical medicine today.

Also, we need to learn more about combination antifungal therapy, e. about the effects of sequential blockade at two or more sites, and about the combination of antifungal agents with cytokines in an attempt to augment the inflammatory and immune responses of patients.

This overview of new antifungal drug development reflects the increased interest in this field of infectious diseases and demonstrates that, although some progress has been made, further efforts are necessary to develop more promising agents against invasive fungal disease.

Although new antifungal agents are being developed, therapeutic guidelines are suggested in the Table with the realization that these guidelines are likely to be adapted, based on new clinical investigation as well as the preferences of individuals.

Treatment guidelines adapted from references 1 , 13 , 24 and Andriole, V. Current and future therapy of invasive fungal infections.

In Current Clinical Topics in Infectious Diseases, Vol. Blackwell Sciences, Malden, MA. Groll, A. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development.

Advances in Pharmacology 44 , — Anaissie, E. Opportunistic mycoses in the immuno-compromised host: experience at a cancer center and review. Clinical Infectious Diseases 14, Suppl.

Pfaller, M. The impact of changing epidemiology of fungal infections in the s. European Journal of Microbiology and Infectious Diseases 11 , — Richardson, M.

Opportunistic and pathogenic fungi. Journal of Antimicrobial Chemotherapy 28, Suppl. A, 1 — Walsh, T. Invasive fungal infections: problems and challenges in developing new antifungal compounds. In Emerging Targets in Antibacterial and Antifungal Chemotherapy Sutcliffe, J.

Eds , pp. Georgopapadakou, N. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrobial Agents and Chemotherapy 40 , — Beck-Sague, C. Secular trends in the epidemiology of nosocomial fungal infections in the U. Journal of Infectious Diseases , — Denning, D.

Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. B, 1 —6. Diamond, R. The growing problem of mycoses in patients infected with the human immunodeficiency virus. Reviews of Infectious Diseases 13 , —6. Vazquez, J. Nosocomial acquisition of Candida albicans: an epidemiologic study.

Bodey, G. Antifungal agents. In Candidosis: Pathogenesis, Diagnosis and Treatment Bodey, G. Raven Press, New York. Eds Pocket Guide to Systemic Antifungal Therapy. Scientific Therapeutics, Springfield, NJ. Current, W. et al. Glucan biosynthesis as a target for antifungal: the echinocandin class of antifungal agents.

In Antifungal Agents: Discovery and Mode Dixon, G. BIOS, Oxford. Bolard, J. How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochemica et Biophysica Acta , — Warnock, D.

Amphotericin B: an introduction. B, 27 — Hazen, E. Science , Fungicidin, an antibiotic produced by a soil actinomycete. Proceedings of the Society of Experimental Biology 76 , Bennett, J. Developing drugs for the deep mycoses: A short history.

In New Strategies in Fungal Disease Bennett, J. Churchill Livingstone, London. Gold, W. Amphotericins A and B: antifungal antibiotic produced by streptomycete. In vitro studies. Antibiotic Annals , — The use of amphotericin B in man. Journal of the American Medical Association , — Kravetz, H.

Oral administration of solubilized amphotericin B. New England Journal of Medicine , —4. Gallis, H. Amphotericin B: 30 years of clinical experience.

Reviews of Infectious Diseases 12 , — In Current ID Drugs Andriole, V. Current Medicine, Philadelphia, PA. Amphotericin B: a commentary on its role as an antifungal agent and as a comparative agent in clinical trials.

Clinical Infectious Diseases 22, Suppl. Hiemenz, J. Lipid formulations of amphotericin B: recent progress and future directions. Lopez-Berestein, G. Treatment of systemic fungal infections with liposomal amphotericin B.

Archives of Internal Medicine , —6. Kline, S. Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex. Clinical Infectious Diseases 21 , —8.

Janknegt, R. Current Opinion in Infectious Diseases 9 , —6. Oppenheim, B. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses.

Clinical Infectious Diseases 21 , — Bowden, R. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant.

Sharkey, P. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clinical Infectious Diseases 22 , — White, M. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs.

amphotericin B in the empirical treatment of fever and neutropenia. Clinical Infectious Diseases 27 , — Wingard, J. Conventional versus lipid formulations of amphotericin B. In Focus on Fungal Infections VII Anaissie, E. San Antonio, Texas, March 12— Imedex Inc.

Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in cases. Clinical Infectious Diseases 26 , — Joly, V. Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or intra-lipid for the treatment of AIDS-associated cryptococcal meningitis.

Clinical Infectious Diseases 23 , — Wallace, T. Nyotran liposomal nystatin activity against disseminated Aspergillus fumigatus in neutropenic mice. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, Abstract B53, p.

American Society for Microbiology, Washington, DC. Gonzalez, C. Efficacy of a lipid formulation of nystatin against invasive pulmonary aspergillosis. Abstract B54, p. Rimaroli, C. In vitro activity of a new polyene, SPA-S, against yeasts.

Antimicrobial Agents and Chemotherapy 42 , —3. Grunberg, E. Chemotherapeutic activity of 5-fluorocytosine. Antimicrobial Agents and Chemotherapy , —8.

Sonne, L. Flucytosine to counter systemic mycoses. Drug Therapy 3 , 55 — Plempel, M. First clinical experience in systemic mycoses with a new oral broad spectrum antimycotic.

Deutsche Medizinische Wochenschrift 94 , Edwards, J. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.

New England Journal of Medicine , — Management of invasive candidal infections: results of a prospective randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Kauffman, C.

Role of azoles in antifungal therapy. Czwerwiec, F. Long-term survival after fluconazole therapy of candidal prosthetic valve endocarditis. American Journal of Medicine 94 , —6.

Saag, M. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cyrptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. New England Journal of Medicine , 83 —9. van der Horst, C. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome.

National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. New England Journal of Medicine , 15 — Singh, N.

and zygomycetes e. Mucor spp. and Pseudoallescheria boydii are often resistant. Topical preparations are also available. Intravenous amphotericin B has been the mainstay of effective therapy for invasive fungal infections.

Nephrotoxicity is the most serious side effect of amphotericin B therapy. Almost every patient develops some abnormality in renal function. Lipid formulations of amphotericin B. Liposomal preparations of amphotericin B have been used to reduce the nephrotoxiciy of conventional amphotericin B.

Clinical responses in patients with invasive aspergillosis appear slightly better in the lipid formulation-treated groups compared with retrospective case control groups treated with conventional amphotericin B. Some important questions about the use of amphotericin B lipid preparations remain unanswered.

Do they have long-term toxicity? Is there an optimal dose schedule and what is the most cost-effective way to use them? Unfortunately, although amphotericin B lipid preparations have reduced nephrotoxicity they have not produced substantial improvements in efficacy in many of the clinical settings in which they have been evaluated.

Some physicians have used a locally prepared variant of lipid-associated amphotericin B made by mixing conventional amphotericin B with Intralipid, Kabi Pharmacia, Saint-Quentin-en-Yvelines, France, for intravenous infusion. Licensed preparations of lipid formulations of amphotericin B should be considered in patients with invasive fungal infections who have dose-limiting renal insufficiency, in patients intolerant of amphotericin B and for specific fungal infections that are progressive despite treatment with amphotericin B.

A liposomal preparation of nystatin has been studied in neutropenic animals with invasive pulmonary aspergillosis rabbits and disseminated aspergillosis mice. Liposomal nystatin improved survival and reduced the tissue burden of aspergillus in these neutropenic animals.

A new polyene, SPA-S, has been studied in vitro against strains of Candida, Cryptococcus and Saccharomyces spp. and has better activity in vitro than conventional amphotericin B. The antifungal activity of 5-fluorocytosine was discovered later and was reported in in a murine model of candidosis.

Uridine 5-monophosphate pyrophosphorylase then converts 5-fluorouracil into fluorodeoxyuridine monophosphate, which inhibits thymidylate synthetase and interferes with DNA synthesis. Although flucytosine is active in vitro against Candida spp.

including C. glabrata , C. neoformans and Aspergillus spp. Although flucytosine, primarily in combination with amphotericin B, is used by some clinicians in the treatment of candida endophthalmitis and meningitis, cryptococcal meningitis and in trichosporonosis, 1 ,12 ,13 the development of newer, more effective and less toxic antifungal agents is likely to decrease flucytosine use in the future.

The initial azole compounds were the imidazoles clotrimazole, miconazole and ketoconazole , which were then followed by the triazoles, fluconazole and itraconazole.

The azoles inhibit fungal cytochrome P 3A-dependent Cα-demethylase which is responsible for the conversion of lanosterol to ergosterol. This leads to the depletion of ergosterol in the fungal cell membrane.

The azoles are primarily active against C. albicans, C. neoformans, C. immitis, H. capsulatum, B. dermatitidis, P. brasiliensis; C. glabrata, Aspergillus spp.

and zygomycetes are resistant to currently available azoles. Clotrimazole, discovered in , 42 cannot be given parenterally, has poor oral absorption and is used for the treatment of oral and vaginal candidosis. An intravenous preparation was marketed but this had suboptimal efficacy and it is now rarely used.

Ketoconazole was discovered in , and has good oral absorption, a broad spectrum of activity and low toxicity, although it may be hepatotoxic and does produce endocrine abnormalities by suppression of testosterone and ACTH-stimulated cortisol synthesis.

Oral ketoconazole is effective in patients with candidosis, coccidioidomycosis, blastomycosis, histoplasmosis, paracoccidioidomycosis and cutaneous dermatophyte infections. Ketoconazole is highly protein bound, has poor CNS penetration and is not suitable for treating CNS infections.

Fluconazole was formulated in It is a novel bi-striazole, is metabolically stable and water soluble and has low lipophilicity and plasma protein binding.

It is active by both oral and intravenous routes which have identical pharmacokinetics, i. once-daily dosing, high blood levels and rapid equilibration of drug in the body with good tissue distribution, including penetration into the cerebrospinal fluid.

Fluconazole is well tolerated and has a very low incidence of side effects and a broad spectrum of antifungal activity, except against Aspergillus spp.

Fluconazole is one of the most effective agents for the treatment of oropharyngeal and oesophageal candidosis, especially in patients with AIDS or cancer, and is extremely effective for the treatment of vaginal candidosis.

Fluconazole has emerged as the drug of choice for coccidioidal meningitis, 1 ,2 ,50 although it is no more effective than other azoles for disseminated non-meningeal coccidioidomycosis. Itraconazole, discovered in , is another triazole antifungal agent with broad-spectrum antifungal activity, including activity against Aspergillus spp.

It is very insoluble, is only available in oral form and may be given once daily. However, higher does not to exceed a total daily dose of mg may be required in serious infections and should be given in two divided doses each day. Since its bioavailability after oral administration may be erratic, maximal absorption is optimal when itraconazole is given with meals.

Itraconazole has established efficacy as primary treatment and maintenance of mild-to-moderate, non-meningeal histoplasmosis in HIV-infected patients and for prevention of relapse in AIDS patients with disseminated histoplasmosis.

Prolonged oral absorption, with slow attainment of steady-state drug levels, and the lack of an intravenous formulation are impediments to itraconazole treatment. It has a chemical structure similar to fluconazole and has broad antifungal activity including in-vitro and in-vivo activity against Aspergillus spp.

Phase III clinical trials are nearly completed. SCH is a potent antifungal triazole with excellent in-vitro activity against Candida spp. and zygomycetes and potent efficacy in animal models of pulmonary blastomycocis, cerebral cryptococcosis, disseminated histoplasmosis, systemic coccidioidomycosis and systemic candidosis.

BMS ER is a very potent antifungal triazole with excellent in-vitro and in-vivo activity against Candida spp. neoformans, Aspergillus fumigatus, Trichosporon beigelli and P.

The echinocandins are cyclic lipopeptide fungicidal agents. They act by preventing cell wall synthesis by non-competitive inhibition of 1,3-β- d -glucan synthase, an enzyme which is absent in mammalian cells. The echinocandin compound, LY , is nearest to clinical development.

It has excellent activity against Candida and Aspergillus spp. in vitro and in animal models. In clinical studies, LY is well tolerated and has linear kinetics and a long plasma half-life 30—40 h so that once-daily dosing is anticipated.

The pneumocandins are echinocandin analogues one of the classes of echinocandin lipopeptides. They are cyclic hexapeptides which inhibit 1,3-β- d -glucan synthase which synthesizes a critical structural cell wall component.

They also have activity against Candida and Aspergillus spp. A few pneumocandin compounds have been developed but only MK L has undergone substantial investigation. The pradimicins and benanomicins are fungicidal compounds. They appear to bind, in a calcium-dependent manner, to cell wall mannoproteins and this causes osmotic lysis and leakage of intracellular contents, particularly potassium, ultimately leading to cell death.

Calcium-dependent binding to mammalian cells has not been observed with this class of antifungal agents. BMS was shown to be effective, though less active than conventional amphotericin B, in animal models of aspergillosis, candidosis and cryptococcosis, 1 ,2 ,7 ,76 ,77 but clinical investigation with BMS has been discontinued because of hepatotoxicity in human volunteers.

The nikkomycins are competitive inhibitors of fungal chitin synthase enzymes which are necessary for fungal cell wall synthesis.

Chitin is a linear polymer of β- 1,4 -linked N -acetylglucosamine residues and is synthesized on the cytoplasmic surface of the plasma membrane. Nikkomycin Z SP is effective in vitro and in vivo against the chitinous, dimorphic fungi C.

immitis and B. dermatitidis, but only modestly active in vitro against C. neoformans and H. neoformans and A. fumigatus, and in vivo against H. Very recently, a new synthetic antifungal agent, l -lysyl- l -norvalyl- N 3 - 4-methoxylfumaroyl - l -2,3-diaminopropanoic acid Lys-Nva-FMDP , which acts as an inhibitor of glucosephosphate synthase an enzyme which catalyses the first step in chitin biosynthesis , has been shown to inhibit growth of H.

capsulatum in vitro and in vivo. Recombinant human chitinase was recently produced. It was found to have efficacy in animal models of candidosis and aspergillosis, but was found to have significantly better activity when combined with conventional amphotericin B.

The allylamines and thiocarbamates are synthetic fungicidal agents that are reversible, non-competitive inhibitors of squalene epoxidase, an enzyme which, together with squalene cyclase, converts squalene to lanosterol.

In fungal cells, if squalene is not converted to lanosterol, the conversion of lanosterol to ergosterol is prevented.

The resulting ergosterol depletion affects fungal cell membrane structure and function. Naftifine is a topical preparation whereas terbinafine Lamisil; SF, Sandoz Pharmaceuticals is an oral systemic agent.

The allylamine, naftifine, is considered an effective topical agent for treatment of dermatophyte infections of the skin. Terbinafine has good in-vitro activity against Aspergillus spp. and other filamentous fungi, but variable activity against yeasts.

However, terbinafine has been shown to be effective in vitro against some strains of Aspergillus spp. boydii, when combined with azoles or amphotericin B, 1 ,83 ,84 ,85 ,86 and in an animal model of aspergillosis when combined with amphotericin B.

The sordarins are a new class of potential antifungal agents. They inhibit protein synthesis in pathogenic fungi: the primary target for sordarin activity has been identified recently as elongation factor 2. A number of new sordarins are being evaluated, including GM, GM, GM, GM, GM and GR neoformans, P.

carinii and some filamentous fungi. or Scedosporium apiospermum. Cationic peptides, both naturally occurring and synthetic derivatives, bind to ergosterol and cholesterol in fungal cell membranes, ultimately leading to cell lysis.

neoformans and Fusarium spp. Naturally occurring cationic peptides include cecropins, dermaseptins, indolicin, histatins, bactericidal permeability-increasing factor BPI , lactoferrin and defensins.

The search for new antifungal agents has been expanded as progress in molecular biology has led to a better understanding of important and essential pathways in fungal cell growth and multiplication.

A number of new compounds, some with unidentified mechanisms of action, are under study. Some are quite active in vitro against Candida spp. including azole-resistant strains , C.

neoformans, A. fumigatus and Fusarium spp. albicans in thermally injured mice. The discovery of new molecular targets in both yeasts and filamentous fungi that will render these organisms susceptible to novel antifungal drugs is likely to continue in view of the major challenge by systemic fungal infections in clinical medicine today.

Also, we need to learn more about combination antifungal therapy, e. about the effects of sequential blockade at two or more sites, and about the combination of antifungal agents with cytokines in an attempt to augment the inflammatory and immune responses of patients.

This overview of new antifungal drug development reflects the increased interest in this field of infectious diseases and demonstrates that, although some progress has been made, further efforts are necessary to develop more promising agents against invasive fungal disease.

Although new antifungal agents are being developed, therapeutic guidelines are suggested in the Table with the realization that these guidelines are likely to be adapted, based on new clinical investigation as well as the preferences of individuals.

Treatment guidelines adapted from references 1 , 13 , 24 and Andriole, V. Current and future therapy of invasive fungal infections. In Current Clinical Topics in Infectious Diseases, Vol.

Blackwell Sciences, Malden, MA. Groll, A. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development.

Advances in Pharmacology 44 , — Anaissie, E. Opportunistic mycoses in the immuno-compromised host: experience at a cancer center and review. Clinical Infectious Diseases 14, Suppl.

Pfaller, M. The impact of changing epidemiology of fungal infections in the s. European Journal of Microbiology and Infectious Diseases 11 , — Richardson, M. Opportunistic and pathogenic fungi. Journal of Antimicrobial Chemotherapy 28, Suppl.

A, 1 — Walsh, T. Invasive fungal infections: problems and challenges in developing new antifungal compounds. In Emerging Targets in Antibacterial and Antifungal Chemotherapy Sutcliffe, J. Eds , pp. Georgopapadakou, N. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrobial Agents and Chemotherapy 40 , — Beck-Sague, C.

Secular trends in the epidemiology of nosocomial fungal infections in the U. Journal of Infectious Diseases , — Denning, D. Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host.

B, 1 —6. Diamond, R. The growing problem of mycoses in patients infected with the human immunodeficiency virus. Reviews of Infectious Diseases 13 , —6. Vazquez, J. Nosocomial acquisition of Candida albicans: an epidemiologic study.

Bodey, G. Antifungal agents. In Candidosis: Pathogenesis, Diagnosis and Treatment Bodey, G. Raven Press, New York. Eds Pocket Guide to Systemic Antifungal Therapy. Scientific Therapeutics, Springfield, NJ. Current, W. et al. Glucan biosynthesis as a target for antifungal: the echinocandin class of antifungal agents.

In Antifungal Agents: Discovery and Mode Dixon, G. BIOS, Oxford. Bolard, J. How do the polyene macrolide antibiotics affect the cellular membrane properties?

Biochemica et Biophysica Acta , — Warnock, D. Amphotericin B: an introduction. How is invasive candidiasis treated? Page last reviewed: November 18, Content source: Centers for Disease Control and Prevention , National Center for Emerging and Zoonotic Infectious Diseases NCEZID , Division of Foodborne, Waterborne, and Environmental Diseases DFWED.

home Fungal Diseases. Enter your email to get updates on C. auris Email Address. What's this? Related Links. Fungal Meningitis National Center for Emerging and Zoonotic Infectious Disease Division of Foodborne, Waterborne, and Environmental Diseases Mycotic Diseases Branch.

Chronic aspergillosis and acute candidiasis models or in vitro systems that better replicate the in vivo environment are recommended for monitoring the potential for the development of resistance in vivo, both for the target organism and for commensal fungi at the site of infection and distant body sites.

Use of the same drug class in agriculture and medicine is a key driver for environmental drug resistance in Aspergillus spp. Removing azoles from agriculture is not trivial nor practical, as it would have a significant effect on global food production.

Yet azole resistance in plant pathogens is emerging rapidly in agricultural settings. So what is the future of antifungal development with One Health in mind? Clearly, the development of fungicides for agriculture and antifungals for pharma needs to diverge 4.

Approaches that focus on targets that are crucial for pathogenicity in plants but are different to those in humans may also lead to diverging methods of controlling fungal pathogens. Towards this end, significant technological strides have been made to enable high-throughput identification of virulence determinants by combining functional genomics and next-generation sequencing , Undoubtedly, accelerated development of diverse, differentiated and ring-fenced antifungal pipelines for both agribusiness and pharma are not only the key to developing new fungicidal compounds but are also key to addressing evolving antifungal resistance in the coming years.

How can we stem the tide of emerging antifungal resistance? Currently available strategies to limit the evolution of human fungal pathogens to chemical control include boosting surveillance and antifungal stewardship programmes, both of which require improved diagnosis of IFDs and antifungal resistance; minimizing environmental—clinical dual usage of antifungals; and optimizing resilient combination therapies using existing licensed drugs.

Future strategies to lessen the impact of antifungal resistance largely require treating at-risk individuals with novel antifungal compounds patented solely for clinical use.

Synoptic integrated One Health understanding is necessary to understand not only the complex multifactorial pathways that lead to the emergence of resistance across the fungal kingdom but also potential interventions to mitigate the rate of emergence. a Complex biotic and abiotic interactions lead to occurrence of evolutionary hotspots for antimicrobial resistance AMR development in environmental opportunistic fungi requiring targeted interventions in the environment.

b , c Patient exposures to environmental AMR require enhanced methods of detection with more focus on key fungal life-history factors part b , and new and emerging drug-resistant fungal pathogens that have the potential for global nosocomial carriage and outbreaks in health-care settings require transnational surveillance part c.

A cross-cutting theme is the need for industry to separate development and use of agricultural fungicides from those antifungals that are used in the clinic to develop treatments that are resilient to the evolutionary forces at play in parts a — c. GLASS, Global Antimicrobial Resistance Surveillance System; WHO, World Health Organization.

Widespread prophylactic and empiric prescribing of antifungals to treat suspected IFDs in individuals who are chronically at risk for example, individuals with cystic fibrosis , those who are critically ill and patients with haemato-oncology remains a concern. Effective antifungal stewardship is required to optimize antifungal use and to preserve the limited antifungal arsenal , This is especially relevant for fungal infections that are highly transmissible, such as Candida spp.

and skin-infecting Trichophyton spp. In largely single-centre, historic cohort observational non-randomized studies, antifungal stewardship programmes have consistently demonstrated an improvement in measures such as timely and appropriate antifungal prescribing guideline-driven , the use of diagnostics and drug monitoring as well as a reduction in antifungal consumption, reducing antifungal selective pressures and the development of resistance , , , Although such studies were not designed to demonstrate improved clinical outcomes, the absence of an adverse impact of antifungal stewardship implementation on the incidence of IFDs, length of hospital stay and in-hospital mortality are important findings Antifungal stewardship is underpinned by access to timely and sensitive diagnostics, and although a review of various pre-emptive diagnostic versus empirical antifungal strategies confirmed the suitability of pre-emptive strategies, the optimal strategy and limits have not been defined Combination antimicrobial treatment is an established and effective strategy to prevent the development of secondary AMR for various bacterial and viral infections.

The principle was established in the s in the treatment of tuberculosis, and has been repeated, for example, for HIV treatment in the s and for the treatment of hepatitis C virus more recently Combination therapies with amphotericin B plus flucytosine or fluconazole plus flucytosine in settings where amphotericin B is not available are the established standard of care in cryptococcosis Combining flucytosine and fluconazole can prevent the selection of fluconazole hetero-resistant fungal populations that occur in individuals with cryptococcal meningitis following initial treatment with fluconazole monotherapy In terms of primary, environmentally derived, antifungal resistance, combination treatment of patients may have a limited effect, but combinations could reduce treatment failure due to primary resistance and limit the development of secondary, clinical antifungal resistance.

Combination treatments may be additive or synergistic in terms of antimicrobial efficacy, and further work is needed to further their potential in a wide range of life-threatening fungal infections.

For invasive aspergillosis, consistent in vitro and animal model data both suggest that combining azole and echinocandin classes increases fungal killing and improves survival , , Animal models suggest a role for combination therapy in azole-resistant invasive aspergillosis , but more work is needed to systematically explore combinations of established and new antifungal agents in experimental models and phase II clinical studies before moving to adequately powered phase III trials.

In comparison with opportunistic fungal pathogens, C. auris can persist and spread within intensive care units and other health-care settings, leading to severe and intractable nosocomial outbreaks. Echinocandin monotherapy is commonly used to treat patients with C.

auris , which is generally resistant to fluconazole. As this approach may facilitate the evolution and spread of multidrug-resistant isolates 16 , combination therapy strategies must be evaluated systematically to mitigate risk in this now globalized fungus. Other approaches to protect existing antifungals include exploiting host-directed approaches to manage antifungal resistance.

These include immunotherapy , fungal vaccines and antibodies to fungal targets Because IFDs are most common in immunocompromised hosts, host-directed immunotherapies, including recombinant cytokines, monoclonal antibodies and fungus-specific engineered T cells , have been in development.

The use of interferon-γ to prevent and treat invasive aspergillosis in patients with chronic granulomatous disease was the first successful host-directed antifungal immunotherapy Since then, patient case series describing successful use of the TLR7 agonist imiquimod in chromoblastomycosis and granulocyte—macrophage colony-stimulating factor GM-CSF therapy for central nervous system candidiasis associated with CARD9 deficiency have been reported.

These advances highlight the potential for host-directed approaches to lessen the pressure on antifungal drugs. Moreover, cell-based therapies, including dendritic cell transfer and chimeric antigen receptor CAR T cell therapy, have shown promising results in vitro but require evaluation in clinical trials.

The combination of immunotherapeutics with conventional antifungal therapy also holds promise. Numerous candidate fungal vaccines have been studied in the preclinical setting , but only the C. albicans recombinant Als3 protein vaccine has shown promising results in phase II clinical trials Advancing antifungal vaccines will require overcoming several hurdles, especially the ubiquitous nature of fungi in the human holobiont , and the expected suboptimal immune response in those people most at risk for IFDs Also showing promise are antibodies and fungal pattern recognition receptors that potentially target antifungal agents for pathogen delivery Preclinical studies of dectin-2 coupled to liposomal amphotericin B have shown encouraging results in experimental pulmonary aspergillosis and may help reduce antifungal toxicity in the host.

However, although host-directed antifungal strategies, alone or in combination with conventional antifungals, hold immense promise, furthering and financing these novel strategies from the laboratory to clinical trials will be a significant challenge in the coming decade.

Furthermore, the breadth and diversity of the fungal kingdom ensures a bottomless reservoir of new pathogens, alongside endless supplies of variants of old enemies, that readily adapt and evolve when exposed to antifungal chemicals.

The sheer ecological breadth of fungal species, with their unique and varied ecological trophisms, in rapidly changing environments means that human health will always be enmeshed with the complex ecology of fungal communities, whether commensal or environmental.

Similarly, our simultaneous need to control fungal disease in agricultural environments and the clinic means that integrated responses take these needs into consideration. Pathogenic fungi are widely vectored both actively and passively, such that tackling antifungal resistance both in the clinic and in the field requires a coordinated global response.

The current lack of transnational support for networks, infrastructures, research funding and career development must be addressed through greater coordination between policymakers, funding agencies and researchers, and include the producers and users of antifungals. Bongomin, F.

Global and multi-national prevalence of fungal diseases-estimate precision. Article Google Scholar. Brown, G. et al. Hidden killers: human fungal infections. Article PubMed PubMed Central Google Scholar.

Robbins, N. Molecular evolution of antifungal drug resistance. Article CAS PubMed Google Scholar. Fisher, M. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science , — Verweij, P.

The one health problem of azole resistance in Aspergillus fumigatus : current insights and future research agenda. Fungal Biol. Rhodes, J. Global epidemiology of emerging Candida auris. Article PubMed Google Scholar. Antibiotic resistance threats in the United States, Centers for Disease Control and Prevention www.

html Threats posed by the fungal kingdom to humans, wildlife, and agriculture. Rodrigues, M. Fungal diseases as neglected pathogens: a wake-up call to public health officials. PLoS Negl. Baker, S. Genomic insights into the emergence and spread of antimicrobial-resistant bacterial pathogens.

Article CAS PubMed PubMed Central Google Scholar. Edlind, T. Mutational analysis of flucytosine resistance in Candida glabrata. Agents Chemother.

Berman, J. Drug resistance and tolerance in fungi. Ballard, E. In-host microevolution of Aspergillus fumigatus : a phenotypic and genotypic analysis. Fungal Genet. Shields, R. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.

Steinmann, J. Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. Pristov, K. Resistance of Candida to azoles and echinocandins worldwide. Johnson, E. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis.

Laverdiere, M. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. Joint Programming Initiative on Antimicrobial Resistance. JPIAMR Strategic Research and Innovation Agenda on Antimicrobial Resistance.

pdf Public Health England. Laboratory Surveillance of Candidaemia in England, Wales and Northern Ireland: Public Health England, Wauters, J. Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study.

Intensive Care Med. Armstrong-James, D. Confronting and mitigating the risk of COVID associated pulmonary aspergillosis. Garg, D. Coronavirus disease COVID associated mucormycosis CAM : case report and systematic review of literature. Mycopathologia , — Janssen, N. Multinational observational cohort study of COVIDassociated pulmonary aspergillosis.

Arastehfar, A. COVIDassociated candidiasis CAC : an underestimated complication in the absence of immunological predispositions? Singh, A.

Mucormycosis in COVID a systematic review of cases reported worldwide and in India. Diabetes Metab. Disease surveillance in recombining pathogens: multilocus genotypes identify sources of human Coccidioides infections. Natl Acad. USA 99 , — Ashu, E. Global population genetic analysis of Aspergillus fumigatus.

Sewell, T. Nonrandom distribution of azole resistance across the global population of Aspergillus fumigatus. Population genomics confirms acquisition of drug resistance Aspergillus fumigatus infection by humans from the environment Nat. in press. Vanhove, M.

Steinberg, G. A lipophilic cation protects crops against fungal pathogens by multiple modes of action. Toda, M. Trends in agricultural triazole fungicide use in the United States, — and possible implications for antifungal-resistant fungi in human disease.

Health Perspect. Article CAS Google Scholar. Chen, Y. High azole resistance in Aspergillus fumigatus isolates from strawberry fields, China, European Centre for Disease Prevention and Control.

Risk Assessment on the Impact of Environmental Usage of Triazoles on the Development and Spread of Resistance to Medical Triazoles in Aspergillus Species ECDC, Snelders, E.

Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Schoustra, S. New Insights in the Development of Azole-resistance in Aspergillus fumigatus RIVM: National Institute for Public Health and the Environment, Elevated prevalence of azole-resistant aspergillus fumigatus in urban versus rural environments in the United Kingdom.

Zhou, D. Extensive genetic diversity and widespread azole resistance in greenhouse populations of Aspergillus fumigatus in Yunnan, China. Burks, C. Azole-resistant Aspergillus fumigatus in the environment: identifying key reservoirs and hotspots of antifungal resistance.

PLoS Pathog. Dunne, K. Intercountry transfer of triazole-resistant Aspergillus fumigatus on plant bulbs. Shelton, J. Campaign-based citizen science for environmental mycology: the science solstice and summer soil-stice projects to assess drug resistance in air- and soil-borne Aspergillus fumigatus.

Theory Pract. Google Scholar. Rocchi, S. Molecular epidemiology of azole-resistant Aspergillus fumigatus in France shows patient and healthcare links to environmentally occurring genotypes. Cell Infect. Hagiwara, D. A novel Zn2-Cys6 transcription factor AtrR plays a key role in an azole resistance mechanism of Aspergillus fumigatus by co-regulating cyp51A and cdr1B expressions.

Article PubMed PubMed Central CAS Google Scholar. Paul, S. AtrR is an essential determinant of azole resistance in Aspergillus fumigatus. Yasmin, S. Mevalonate governs interdependency of ergosterol and siderophore biosyntheses in the fungal pathogen Aspergillus fumigatus. USA , E—E Carneiro, H.

Hypervirulence and cross-resistance to a clinical antifungal are induced by an environmental fungicide in Cryptococcus gattii. Total Environ. Kamthan, A. Expression of C-5 sterol desaturase from an edible mushroom in fisson yeast enhances its ethanol and thermotolerance. PLoS ONE 12 , e Duong, T.

Azole-resistant Aspergillus fumigatus is highly prevalent in the environment of Vietnam, with marked variability by land use type. Van Rhijn, N. The consequences of our changing environment on life threatening and debilitating fungal diseases in humans.

Casadevall, A. On the emergence of Candida auris : climate change, azoles, swamps, and birds. Tackling emerging fungal threats to animal health, food security and ecosystem resilience.

B Lond. B Biol. Berkow, E. Antifungal susceptibility testing: current approaches. Clancy, C. Levy, H. The value of bronchoalveolar lavage and bronchial washings in the diagnosis of invasive pulmonary aspergillosis.

White, P. Pneumocystis jirovecii pneumonia: epidemiology, clinical manifestation and diagnosis. Fungal Infect. in Antifungal Susceptibility Testing and Resistance Ch.

Oxford Univ. Press, Bader, O. Fungal species identification by MALDI-ToF mass spectrometry. Methods Mol. Vatanshenassan, M. Proof of concept for MBT ASTRA, a rapid matrix-assisted laser desorption ionization—time of flight mass spectrometry MALDI-TOF MS -based method to detect caspofungin resistance in Candida albicans and Candida glabrata.

Zvezdanova, M. Detection of azole resistance in Aspergillus fumigatus complex isolates using MALDI-TOF mass spectrometry.

Garcia-Effron, G. Molecular markers of antifungal resistance: potential uses in routine practice and future perspectives. Chong, G. Interspecies discrimination of A. fumigatus and siblings A. lentulus and A. felis of the Aspergillus section Fumigati using the AsperGenius® assay.

Leach, L. A rapid and automated sample-to-result Candida auris real-time PCR assay for high-throughput testing of surveillance samples with the BD max open system. PCR-based detection of Aspergillus fumigatus Cyp51A mutations on bronchoalveolar lavage: a multicentre validation of the AsperGenius assay® in patients with haematological disease suspected for invasive aspergillosis.

Montesinos, I. Evaluation of a new commercial real-time PCR assay for diagnosis of Pneumocystis jirovecii pneumonia and identification of dihydropteroate synthase DHPS mutations. Perlin, D. Culture-independent molecular methods for detection of antifungal resistance mechanisms and fungal identification.

Hou, X. Rapid detection of ERGassociated azole resistance and FKS-associated echinocandin resistance in Candida auris. Pham, C. Development of a Luminex-based multiplex assay for detection of mutations conferring resistance to echinocandins in Candida glabrata.

Yu, L. Rapid detection of azole-resistant Aspergillus fumigatus in clinical and environmental isolates by use of a lab-on-a-chip diagnostic system.

Novak-Frazer, L. Deciphering Aspergillus fumigatus cyp51A-mediated triazole resistance by pyrosequencing of respiratory specimens. Walker, T. Tuberculosis is changing. Lancet Infect. Brackin, A. Fungal genomics in respiratory medicine: what, how and when? Chow, N. Tracing the evolutionary history and global expansion of Candida auris using population genomic analyses.

Genomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris. Microbes Infect. PubMed PubMed Central Google Scholar. Pasic, L. Consensus multilocus sequence typing scheme for Pneumocystis jirovecii.

Ponce, C. High prevalence of Pneumocystis jirovecii dihydropteroate synthase gene mutations in patients with a first episode of pneumocystis pneumonia in Santiago, Chile, and clinical response to trimethoprim—sulfamethoxazole therapy.

Bueid, A. Azole antifungal resistance in Aspergillus fumigatus: and SENTRY program participating sites — Open Forum Infect. Astvad, K. Update from a year nationwide fungemia surveillance: increasing intrinsic and acquired resistance causes concern.

Escribano, P. Azole resistance survey on clinical Aspergillus fumigatus isolates in Spain. Rivero-Menendez, O. Triazole resistance in Aspergillus spp. Chowdhary, A. Candida auris : a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally.

First meeting of the WHO Antifungal Expert Group on Identifying Priority Fungal Pathogens: Meeting Report World Health Organization, Alexander, B. Increasing echinocandin resistance in Candida glabrata : clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.

A population genomics approach to assessing the genetic basis of within-host microevolution underlying recurrent cryptococcal meningitis infection. G3 7 , — Hens, B. In silico modeling approach for the evaluation of gastrointestinal dissolution, supersaturation, and precipitation of posaconazole.

Li, X. A physiologically based pharmacokinetic model of voriconazole integrating time-dependent inhibition of CYP3A4, genetic polymorphisms of CYP2C19 and predictions of drug-drug interactions. Gerhart, J. Physiologically-based pharmacokinetic modeling of fluconazole using plasma and cerebrospinal fluid samples from preterm and term infants.

CPT Pharmacomet. Campoli, P. Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis. Di Paolo, M. JAC Antimicrob.

Hope, W. Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality. Tangden, T. Chen, G. Targeting the adaptability of heterogeneous aneuploids. Cell , — Ward, D. Trends in clinical development timeframes for antiviral drugs launched in the UK, — a retrospective observational study.

BMJ Open 5 , e Jorda, A. Maertens, J. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi SECURE : a phase 3, randomised-controlled, non-inferiority trial. Lancet , — Jorgensen, K.

EUCAST susceptibility testing of isavuconazole: MIC data for contemporary clinical mold and yeast isolates. Buil, J. In vitro activity of the novel antifungal compound F against difficult-to-treat Aspergillus isolates. Larwood, D.

Nikkomycin Z-ready to meet the promise? Nix, D. Pharmacokinetics of Nikkomycin Z after single rising oral doses. Brockhurst, M. Assessing evolutionary risks of resistance for new antimicrobial therapies.

Wang, M. Bidirectional cross-kingdom RNAi and fungal uptake of external RNAs confer plant protection. Plants 2 , Macdonald, D. Inducible cell fusion permits use of competitive fitness profiling in the human pathogenic fungus Aspergillus fumigatus.

CAS PubMed Google Scholar. Lee, K. Systematic functional analysis of kinases in the fungal pathogen Cryptococcus neoformans.